Skip to main content

2.

2

The ICB is a promising therapy, but clinicians encounter several difficulties. MiRNAs can be suitable partners of the ICB and be used to predict the response to therapy, detect and treat the side effects of anti-immune checkpoint antibodies and potentiate the effect of the ICB (ICB – immune checkpoint blockade; irAE – immune related adverse events).